Sellas Life Sciences Group Inc (SLS)

Sellas Life Sciences Group Inc (SLS) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $2.3B; returns 1 day +1.7%, 1 week +15.6%, 1 year +504.2%.

SELLAS Life Sciences Group Inc. is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies and targeted therapies. The company's lead product candidate is galinpepimut-S (GPS), a peptide-based cancer immunotherapeutic agent that targets the Wilms tumor 1 (WT1) protein, which is overexpressed in various hematologic and solid tumors.

Groups SLS belongs to

• Biotechnology
• Clinical Stage Biotech
• Oncology
• Healthcare
• Clinical Stage
• Cancer Therapeutics
• Immunotherapy
• Life Sciences
• Biopharmaceutical
• Clinical Stage Biopharma
• Hematologic Malignancies
• Hematology
• Pharmaceuticals
• Ovarian Cancer

SLS financial model: income statement, cash flow and balance sheet